Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|7|5|331-337

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.7, Iss.5, 2006-10, pp. : 331-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 3, 2006-06 ,pp. : 185-198

Bentham Science Publishers

Access to resources Recommend Favorite

Oncogenic Variant RON160 Expression in Breast Cancer and its Potential as a Therapeutic Target by Small Molecule Tyrosine Kinase Inhibitor

By  

Current Cancer Drug Targets, Vol. 13, Iss. 6, 2013-07 ,pp. : 686-697

Bentham Science Publishers

Access to resources Recommend Favorite

Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase

By  

Current Cancer Drug Targets, Vol. 3, Iss. 1, 2003-02 ,pp. : 31-40

Bentham Science Publishers

Access to resources Recommend Favorite

Aurora-A kinase: a novel target both for cellular immunotherapy and molecular target therapy against human leukemia

By Ochi Toshiki   Fujiwara Hiroshi   Yasukawa Masaki  

Expert Opinion on Therapeutic Targets, Vol. 13, Iss. 12, 2009-12 ,pp. : 1399-1410

Informa Healthcare

Access to resources Recommend Favorite

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias

By Banerji Lolita   Sattler Martin  

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 3, 2004-06 ,pp. : 221-239

Informa Healthcare

Access to resources Recommend Favorite